Cilostazol eliminates adverse smoking outcome in patients with drug-eluting stent implantation - Analysis of longer-term follow-up of the CILON-T randomized trial -

Hack Lyoung Kim, Jung Won Suh, Seung Pyo Lee, Hyun Jae Kang, Bon Kwon Koo, Young Seok Cho, Tae Jin Youn, In Ho Chae, Dong Ju Choi, Seung-Woon Rha, Jang Ho Bae, Taek Geun Kwon, Jang Whan Bae, Myeong Chan Cho, Hyo Soo Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The present study investigated whether cilostazol can eliminate adverse smoking outcome after percutaneous coronary intervention (PCI). Methods and Results: A total of 914 patients with successful drug-eluting stent (DES) implantation were randomly assigned to dual antiplatelet therapy (DAT; aspirin and clopidogrel, n=457) or to triple antiplatelet therapy (TAT; DAT with cilostazol, n=457). The effect of smoking on 2-year major adverse cardio/cerebrovascular events (MACCE) in both the TAT and DAT groups was evaluated. Total MACCE were not significantly different between the 2 anti-platelet regimens (9.8% in TAT vs. 11.4% in DAT groups, P=0.45), but the adverse effects of smoking on clinical outcome were different between DAT vs. TAT. Current smokers had a higher prevalence of MACCE than non-smokers in the DAT group (16.7% vs. 9.5%, P=0.04). In the TAT group, however, the adverse effect of smoking was abolished (9.2% vs. 10.1%, P=0.85). Regarding the effects of smoking on the antiplatelet effects of DAT or TAT, post-treatment platelet reactivity (in P2Y12 reaction units; PRU) in current smokers was not significantly lower than that in non-smokers in the DAT group, whereas, in the TAT group, it was significantly lower than that of non-smokers (189±88 vs. 216±89 PRU, P=0.01). Conclusions: Adverse clinical effects of smoking may be eliminated by the addition of cilostazol to DAT after DES implantation. This may be due to the stimulation of cilostazol's antiplatelet effects by smoking.

Original languageEnglish
Pages (from-to)1420-1427
Number of pages8
JournalCirculation Journal
Volume78
Issue number6
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Drug-Eluting Stents
Smoking
clopidogrel
Blood Platelets
Percutaneous Coronary Intervention
cilostazol
Aspirin
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cilostazol eliminates adverse smoking outcome in patients with drug-eluting stent implantation - Analysis of longer-term follow-up of the CILON-T randomized trial -. / Kim, Hack Lyoung; Suh, Jung Won; Lee, Seung Pyo; Kang, Hyun Jae; Koo, Bon Kwon; Cho, Young Seok; Youn, Tae Jin; Chae, In Ho; Choi, Dong Ju; Rha, Seung-Woon; Bae, Jang Ho; Kwon, Taek Geun; Bae, Jang Whan; Cho, Myeong Chan; Kim, Hyo Soo.

In: Circulation Journal, Vol. 78, No. 6, 01.01.2014, p. 1420-1427.

Research output: Contribution to journalArticle

Kim, HL, Suh, JW, Lee, SP, Kang, HJ, Koo, BK, Cho, YS, Youn, TJ, Chae, IH, Choi, DJ, Rha, S-W, Bae, JH, Kwon, TG, Bae, JW, Cho, MC & Kim, HS 2014, 'Cilostazol eliminates adverse smoking outcome in patients with drug-eluting stent implantation - Analysis of longer-term follow-up of the CILON-T randomized trial -', Circulation Journal, vol. 78, no. 6, pp. 1420-1427. https://doi.org/10.1253/circj.CJ-13-1394
Kim, Hack Lyoung ; Suh, Jung Won ; Lee, Seung Pyo ; Kang, Hyun Jae ; Koo, Bon Kwon ; Cho, Young Seok ; Youn, Tae Jin ; Chae, In Ho ; Choi, Dong Ju ; Rha, Seung-Woon ; Bae, Jang Ho ; Kwon, Taek Geun ; Bae, Jang Whan ; Cho, Myeong Chan ; Kim, Hyo Soo. / Cilostazol eliminates adverse smoking outcome in patients with drug-eluting stent implantation - Analysis of longer-term follow-up of the CILON-T randomized trial -. In: Circulation Journal. 2014 ; Vol. 78, No. 6. pp. 1420-1427.
@article{19c305a0f5704f6d9fee092fe4356a74,
title = "Cilostazol eliminates adverse smoking outcome in patients with drug-eluting stent implantation - Analysis of longer-term follow-up of the CILON-T randomized trial -",
abstract = "Background: The present study investigated whether cilostazol can eliminate adverse smoking outcome after percutaneous coronary intervention (PCI). Methods and Results: A total of 914 patients with successful drug-eluting stent (DES) implantation were randomly assigned to dual antiplatelet therapy (DAT; aspirin and clopidogrel, n=457) or to triple antiplatelet therapy (TAT; DAT with cilostazol, n=457). The effect of smoking on 2-year major adverse cardio/cerebrovascular events (MACCE) in both the TAT and DAT groups was evaluated. Total MACCE were not significantly different between the 2 anti-platelet regimens (9.8{\%} in TAT vs. 11.4{\%} in DAT groups, P=0.45), but the adverse effects of smoking on clinical outcome were different between DAT vs. TAT. Current smokers had a higher prevalence of MACCE than non-smokers in the DAT group (16.7{\%} vs. 9.5{\%}, P=0.04). In the TAT group, however, the adverse effect of smoking was abolished (9.2{\%} vs. 10.1{\%}, P=0.85). Regarding the effects of smoking on the antiplatelet effects of DAT or TAT, post-treatment platelet reactivity (in P2Y12 reaction units; PRU) in current smokers was not significantly lower than that in non-smokers in the DAT group, whereas, in the TAT group, it was significantly lower than that of non-smokers (189±88 vs. 216±89 PRU, P=0.01). Conclusions: Adverse clinical effects of smoking may be eliminated by the addition of cilostazol to DAT after DES implantation. This may be due to the stimulation of cilostazol's antiplatelet effects by smoking.",
keywords = "Cilostazol, Percutaneous coronary intervention, Platelet function test, Smoking",
author = "Kim, {Hack Lyoung} and Suh, {Jung Won} and Lee, {Seung Pyo} and Kang, {Hyun Jae} and Koo, {Bon Kwon} and Cho, {Young Seok} and Youn, {Tae Jin} and Chae, {In Ho} and Choi, {Dong Ju} and Seung-Woon Rha and Bae, {Jang Ho} and Kwon, {Taek Geun} and Bae, {Jang Whan} and Cho, {Myeong Chan} and Kim, {Hyo Soo}",
year = "2014",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-13-1394",
language = "English",
volume = "78",
pages = "1420--1427",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "6",

}

TY - JOUR

T1 - Cilostazol eliminates adverse smoking outcome in patients with drug-eluting stent implantation - Analysis of longer-term follow-up of the CILON-T randomized trial -

AU - Kim, Hack Lyoung

AU - Suh, Jung Won

AU - Lee, Seung Pyo

AU - Kang, Hyun Jae

AU - Koo, Bon Kwon

AU - Cho, Young Seok

AU - Youn, Tae Jin

AU - Chae, In Ho

AU - Choi, Dong Ju

AU - Rha, Seung-Woon

AU - Bae, Jang Ho

AU - Kwon, Taek Geun

AU - Bae, Jang Whan

AU - Cho, Myeong Chan

AU - Kim, Hyo Soo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: The present study investigated whether cilostazol can eliminate adverse smoking outcome after percutaneous coronary intervention (PCI). Methods and Results: A total of 914 patients with successful drug-eluting stent (DES) implantation were randomly assigned to dual antiplatelet therapy (DAT; aspirin and clopidogrel, n=457) or to triple antiplatelet therapy (TAT; DAT with cilostazol, n=457). The effect of smoking on 2-year major adverse cardio/cerebrovascular events (MACCE) in both the TAT and DAT groups was evaluated. Total MACCE were not significantly different between the 2 anti-platelet regimens (9.8% in TAT vs. 11.4% in DAT groups, P=0.45), but the adverse effects of smoking on clinical outcome were different between DAT vs. TAT. Current smokers had a higher prevalence of MACCE than non-smokers in the DAT group (16.7% vs. 9.5%, P=0.04). In the TAT group, however, the adverse effect of smoking was abolished (9.2% vs. 10.1%, P=0.85). Regarding the effects of smoking on the antiplatelet effects of DAT or TAT, post-treatment platelet reactivity (in P2Y12 reaction units; PRU) in current smokers was not significantly lower than that in non-smokers in the DAT group, whereas, in the TAT group, it was significantly lower than that of non-smokers (189±88 vs. 216±89 PRU, P=0.01). Conclusions: Adverse clinical effects of smoking may be eliminated by the addition of cilostazol to DAT after DES implantation. This may be due to the stimulation of cilostazol's antiplatelet effects by smoking.

AB - Background: The present study investigated whether cilostazol can eliminate adverse smoking outcome after percutaneous coronary intervention (PCI). Methods and Results: A total of 914 patients with successful drug-eluting stent (DES) implantation were randomly assigned to dual antiplatelet therapy (DAT; aspirin and clopidogrel, n=457) or to triple antiplatelet therapy (TAT; DAT with cilostazol, n=457). The effect of smoking on 2-year major adverse cardio/cerebrovascular events (MACCE) in both the TAT and DAT groups was evaluated. Total MACCE were not significantly different between the 2 anti-platelet regimens (9.8% in TAT vs. 11.4% in DAT groups, P=0.45), but the adverse effects of smoking on clinical outcome were different between DAT vs. TAT. Current smokers had a higher prevalence of MACCE than non-smokers in the DAT group (16.7% vs. 9.5%, P=0.04). In the TAT group, however, the adverse effect of smoking was abolished (9.2% vs. 10.1%, P=0.85). Regarding the effects of smoking on the antiplatelet effects of DAT or TAT, post-treatment platelet reactivity (in P2Y12 reaction units; PRU) in current smokers was not significantly lower than that in non-smokers in the DAT group, whereas, in the TAT group, it was significantly lower than that of non-smokers (189±88 vs. 216±89 PRU, P=0.01). Conclusions: Adverse clinical effects of smoking may be eliminated by the addition of cilostazol to DAT after DES implantation. This may be due to the stimulation of cilostazol's antiplatelet effects by smoking.

KW - Cilostazol

KW - Percutaneous coronary intervention

KW - Platelet function test

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=84901335928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901335928&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-13-1394

DO - 10.1253/circj.CJ-13-1394

M3 - Article

C2 - 24694769

AN - SCOPUS:84901335928

VL - 78

SP - 1420

EP - 1427

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 6

ER -